Exploring the binding features of polybrominated diphenyl ethers as estrogen receptor antagonists: Docking studies

SAR and QSAR in Environmental Research

Volumn 21, Issue 3, 2010, Pages 351-367

  Yang, W H ^a,b   Wang, Z Y ^a   Liu, H L ^a   Yu, H X ^a  

^a NANJING UNIVERSITY   (China)

^b JIANGSU NORMAL UNIVERSITY   (China)

Author keywords

Antiestrogenicity; Endocrine disruptors; Human estrogen receptor alpha (hER ); Molecular docking

Indexed keywords

ENDOCRINE DISRUPTERS; ETHERS; ORGANIC POLLUTANTS;

ANTI-ESTROGENIC; ANTIESTROGENICITY; BINDING MODES; ENDOCRINE-DISRUPTORS; ESTROGEN RECEPTOR; HUMAN ESTROGEN RECEPTOR ALPHA (HERΑ); HUMAN ESTROGEN RECEPTORS; MOLECULAR DOCKING; POLYBROMINATED DIPHENYLETHERS; RECEPTOR ANTAGONISTS;

BINDING ENERGY;

EID: 77953583262     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/10629361003773971     Document Type: Article

References (33)

1. M. Alaee, P. Arias, A. Sjodin, and A. Bergman, An overview of commercially used brominated flame retardants, their applications, their use patterns in different countries/regions and possible modes of release, Environ. Int. 29 (2003), pp. 683-689.
2. R.C. Hale, M. Alaee, J.B. Manchester-Neesvig, H.M. Stapleton, and M.G. Ikonomou, Polybrominated diphenyl ether flame retardants in the North American environment, Environ. Int. 29 (2003), pp. 771-779.
3. R.A. Hites, Polybrominated diphenyl ethers in the environment and in people: A meta-analysis of concentrations, Environ. Sci. Technol. 38 (2004), pp. 945-956.
4. P.O. Darnerud, G.S. Eriksen, T. Johannesson, P.B. Larsen, and M. Viluksela, Polybrominated diphenyl ethers: Occurrence, dietary exposure, and toxicology, Environ. Health Perspect. 109(Suppl. 1) (2001), pp. 49-68.
5. L.S. Birnbaum and D.F. Staskal, Brominated flame retardants: Cause for concern? Environ. Health Perspect. 112 (2004), pp. 9-17.
6. J. She, A. Holden, M. Tanner, M. Sharp, T. Adelsbach, and K. Hooper, Highest PBDE levels (max 63 ppm) yet found in biota measured in seabird eggs from San Francisco Bay, Organohalogen Compd. 66 (2004), pp. 3939-3944.
7. A. Schecter, O. Papke, K.C. Tung, J. Joseph, T.R. Harris, and J. Dahlgreen, Polybrominated diphenyl ether flame retardants in the U.S. population: Current levels, temporal trends, and comparison with dioxins, dibenzofurans, and polychlorinated biphenyls, J. Occup. Environ. Med. 47 (2005), pp. 199-211.
8. R.J. Law, C.R. Allchin, J. de Boer, A. Covaci, D. Herzke, P. Lepom, S. Morris, J. Tronczynski, and C.A. de Wit, Levels and trends of brominated flame retardants in the European environment, Chemosphere 64 (2006), pp. 187-208.
9. I.A. Meerts, R.J. Letcher, S. Hoving, G. Marsh, A. Bergman, J.G. Lemmen, B. van der Burg, and A. Brouwer, In vitro estrogenicity of polybrominated diphenyl ethers, hydroxylated PDBEs, and polybrominated bisphenol A compounds, Environ. Health Perspect. 109 (2001), pp. 399-407.
10. T. Hamers, J.H. Kamstra, E. Sonneveld, A.J. Murk, M.H.A. Kester, P.L. Andersson, J. Legler, and A. Brouwer, In vitro profiling of the endocrine-disrupting potency of brominated flame retardants, Toxicol. Sci. 92 (2006), pp. 157-173.
11. T.E. Stoker, R.L. Cooper, C.S. Lambright, V.S. Wilson, J. Furr, and L.E. Gray, In vivo and in vitro anti-androgenic effects of DE-71, a commercial polybrominated diphenyl ether (PBDE) mixture, Toxicol. Appl. Pharmacol. 207 (2005), pp. 78-88.
12. M. Mercado-Feliciano and R.M. Bigsby, Hydroxylated metabolites of the polybrominated diphenyl ether mixture DE-71 are weak estrogen receptor - a ligands, Environ. Health Perspect. 116 (2008), pp. 1315-1321.
13. J. Devillers, N. Marchand-Geneste, A. Carpy, and J.M. Porcher, SAR and QSAR modeling of endocrine disruptors, SAR QSAR Environ. Res. 17 (2006), pp. 393-412.
14. J.B. Cross, D.C. Thompson, B.K. Rai, J. Christian Baber, K.Y. Fan, Y.B. Hu, and C. Humblet, Comparison of several molecular docking programs: Pose prediction and virtual screening accuracy, J. Chem. Inf. Model. 49 (2009), pp. 1455-1474.
15. N.M. Mascarenhas and N. Ghoshal, An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation: A case study with CDK2/CyclinA, Eur. J. Med. Chem. 43 (2008), pp. 2807-2818.
16. E. Kellenberger, J. Rodrigo, P. Muller, and D. Rognan, Comparative evaluation of eight docking tools for docking and virtual screening accuracy, Proteins 57 (2004), pp. 225-242.
17. A.N. Jain, Surflex: Fully automatic flexible molecular docking using a molecular similarity-based search engine, J. Med. Chem. 46 (2003), pp. 499-511.
18. S.H. Lee, H.T.M. Van, S.H. Yang, K.T. Lee, Y. Kwon, and W.J. Cho, Molecular design, synthesis and docking study of benz[b]oxepines and 12-oxobenzo[c] phenanthridinones as topoisomerase 1 inhibitors, Bioorg. Med. Chem. Lett. 19 (2009), pp. 2444-2447.
19. H. Van and W. Cho, Structural modification of 3-arylisoquinolines to isoindolo[2,1-b]isoquino- linones for the development of novel topoisomerase 1 inhibitors with molecular docking study, Bioorg. Med. Chem. Lett. 19 (2009), pp. 2551-2554.
20. P.A. Holt, J.B. Chaires, and J.O. Trent, Molecular docking of intercalators and groove-binders to nucleic acids using Autodock and Surflex, J. Chem. Inf. Model. 48 (2008), pp. 1602-1615.
21. A.N. Jain, Effects of protein conformation in docking: improved pose prediction through protein pocket adaptation, J. Comput. Aid. Mol. Design 23 (2009), pp. 355-374.
22. M. Yang, L. Zhou, Z.L. Zuo, X.Y. Tang, J. Liu, and X. Ma, Structure-based virtual screening for glycosyltransferase51, Mol. Simulat. 34 (2008), pp. 849-856.
23. E. Sainz, M. Akeson, S.A. Mantey, R.T. Jensen, and J.F. Battey, Four amino acid residues are critical for high affinity binding of neuromedin B to the neuromedin B receptor, J. Biol. Chem. 273 (1998), pp. 15927-15932.
24. H.X. Liu, E. Papa, and P. Gramatica, Evaluation and QSAR modeling on multiple endpoints of estrogen activity based on different bioassays, Chemosphere 70 (2008), pp. 1889-1897.
25. H. Fang, W.D. Tong, R. Perkins, A.M. Soto, N.V. Prechtl, and D.M. Sheehan, Quantitative comparisons of in vitro assays for estrogenic activities, Environ. Health Perspect. 108 (2000), pp. 723-729.
26. S.Y. Liao, T.J. Chen, T.F. Miao, L. Qian, and K.C. Zheng, Binding orientations, QSAR, and molecular design of thiophene derivative inhibitors, Chem. Biol. Drug Des. 74 (2009), pp. 289-296.
27. A. Brzozowski, A. Pike, Z. Dauter, R. Hubbard, T. Bonn, O. Engstrom, L. Ohman, G. Greene, J. Gustafsson, and M. Carlquist, Molecular basis of agonism and antagonism in the oestrogen receptor, Nature 389 (1997), pp. 753-758.
28. A.K. Shiau, D. Barstad, P.M. Loria, L. Cheng, P.J. Kushner, D.A. Agard, and G.L. Greene, The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen, Cell 95 (1998), pp. 927-937.
29. L.M. Shi, H. Fang, W.D. Tong, J. Wu, R. Perkins, R.M. Blair, W.S. Branham, S.L. Dial, C.L. Moland, and D.M. Sheehan, QSAR models using a large diverse set of estrogens, Chem. Inf. Comput. Sci. 41 (2001), pp. 186-195.
30. L. Celik, J. Lund, and B. Schiøtt, Exploring interactions of endocrine-disrupting compounds with different conformations of the human estrogen receptor r ligand binding domain: A molecular docking study, Chem. Res. Toxicol. 21 (2008), pp. 2195-2206.
31. E.C. Bonefeld-Jørgensen, H.R. Andersen, T.H. Rasmussen, and A.M. Vinggaard, Effect of highly bioaccumulated polychlorinated biphenyl congeners on estrogen and androgen receptor activity, Toxicology 158 (2001), pp. 141-153.
32. V. Krishnan and S. Safe, Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs), and dibenzofurans (PCDFs) as antiestrogens in MCF-7 human breast cancer cells: quantitative structure-activity relationships, Toxicol. Appl. Pharmacol. 120 (1993), pp. 55-61.
33. H. Fang, W.D. Tong, L.M. Shi, R. Blair, R. Perkins, W. Branham, B.S. Hass, Q. Xie, S.L. Dial, C.L. Moland, and D.M. Sheehan, Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens, Chem. Res. Toxicol. 14 (2001), pp. 280-294.